CLAIMS

1. Use of a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one influenza antigen in the manufacture of a medicament for stimulating an immune response to an influenza antigen in a human who is at least 65 years old, wherein the fusion protein is to be administered in a dose ~~greater than about a 0.5µg dose and the human is at least 49 years old~~that generates an immune response to the influenza antigen and at least one adverse systemic reaction by the human who is at least 65 years old related to the flagellin component of the fusion protein is less severe than the dose would generate in a human less than 65 years old.

2. The use of claim 1, wherein the immune response in the human provides protective immunity against an infection consequent to exposure of the human to a source of the influenza antigen.

~~3. The use of claim 1, wherein the human is between 49 years old and about 64 years old.~~

~~4. The use of claim 1, wherein the human is at least 65 years old.~~

~~5~~3. The use of claim 1, wherein the dose is at least one dose selected from the group consisting of a 0.5 µg dose, 1 µg dose, 2 µg dose, 3 µg dose, 4 µg dose, 5 µg dose, 6 µg dose, 7 µg dose, 8µg dose, 10µg dose, 15µg dose, 20 µg dose, 25µg dose and a 30µg dose.

~~6~~4. The use of claim ~~5~~3, wherein the dose is at least one dose selected from the group consisting of a 0.5 µg dose, 1 µg dose, 2 µg dose, 3 µg dose, 4 µg dose, 5 µg dose, 6 g dose, 7 µg dose, and 8µg dose.

~~7~~5. The use of claim ~~5~~3, wherein the dose is at least one dose selected from the group consisting of a 5 µg dose, 6 µg dose, 7 µg dose, 8µg dose, 10µg dose, 15µg dose, 20µg dose, 25µg dose and a 30µg dose.

~~8~~6. The use of claim 1, wherein the dose is at least one dose selected from the group consisting of an 8µg dose, 10µg dose, 15µg dose, 20µg dose, 25 µg dose and a 30µg dose.

~~9. The use of claim 1, wherein the antigen is an influenza antigen.~~

~~10~~7. The use of claim ~~9~~1, wherein the influenza antigen is a hemagglutinin influenza antigen.

~~118~~. The use of claim ~~91~~, wherein the influenza antigen is an influenza A antigen.

~~129~~. The use of claim ~~91~~, wherein the influenza antigen is an influenza B antigen.

~~1310~~. The use of claim ~~91~~, wherein the influenza antigen is an influenza C antigen.

~~1411~~. The use of claim 1, wherein the fusion protein is to be administered intramuscularly to the human.

~~1512~~. The use of claim 1, wherein at least one subsequent dose of the fusion protein is to be administered to the human.

~~1613~~. The use of claim ~~81~~, wherein the fusion protein includes SEQ ID No. 1.

~~17. Use of a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen in the manufacture of a medicament for stimulating an immune response in an elderly human population, wherein the seroresponse rate is at least 75%.~~

~~18. Use of a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen in the manufacture of a medicament for stimulating an immune response in an elderly human population, wherein the seroprotection rate is at least 95%.~~

~~19. Use of a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen in the manufacture of a medicament for stimulating an immune response in an elderly human population, wherein the seroconversion rate is at least 50%.~~

~~20. Use of a composition that includes a fusion protein comprising at least a portion of at least one flagellin and at least a portion of at least one influenza antigen in the manufacture of a medicament for stimulating an immune response in an elderly human population.~~

~~2114~~. Use of claim 1, wherein the influenza antigen of the fusion protein is~~a composition that includes comprising at least a portion of at least one flagellin and at least a portion of at least one antigen~~ associated with a particle in the

manufacture of ~~a~~ the medicament for stimulating ~~an~~ the immune response in ~~a~~ the human~~, wherein the human is at least 49 years old~~.

~~22~~15. The use of claim ~~21~~14, wherein the particle is a virosome, liposome, biodegradable microsphere, self-assembling peptide nanoparticle, virus-like particle or combinations thereof.

~~23~~16. The use of claim ~~22~~15, wherein the particle is a self-assembling peptide nanoparticle.

~~24~~17. The use of claim ~~22~~15, wherein the particle is a virosome.

~~25. The use of claim 19, wherein the composition provides protective immunity against an infection consequent to exposure of the human to a source of antigen.~~

~~26. The use of claim 19, wherein the human is between 49 years old and about 64 years old.~~

~~27. The use of claim 19, wherein the human is at least 65 years old.~~

~~28~~18. The use of claim ~~19~~1, wherein the fusion protein is at least one dose selected from the group consisting of a 8µg dose, 10 µg dose, 15µg dose, 20 µg dose, 25 µg dose and a 30µg dose.

~~29. The use of claim 19, wherein the antigen is an influenza antigen.~~

~~30. The use of claim 29, wherein the influenza antigen is a hemagglutinin influenza antigen.~~

~~31. The use of claim 29, wherein the influenza antigen is an influenza A antigen.~~

~~32. The use of claim 29, wherein the influenza antigen is an influenza B antigen.~~

~~33. The use of claim 29, wherein the influenza antigen is an influenza C antigen.~~

~~34. Use of a composition comprising at least a portion of at least one flagellin and at least a portion of at least one antigen in the manufacture of a medicament for stimulating an immune response in an elderly human population, wherein the seroresponse rate is at least 75%.~~

~~35. Use of a composition comprising at least a portion of at least one flagellin and at least a portion of at least one antigen in the manufacture of a medicament for stimulating an immune response in an elderly human population, wherein the seroprotection rate is at least 95%.~~

~~36. Use of a composition comprising at least a portion of at least one flagellin and at least a portion of at least one antigen in the manufacture of a medicament for stimulating an immune response in an elderly human population, wherein the seroconversion rate is at least 50%.~~

~~37. Use of a composition comprising at least a portion of at least one flagellin and at least a portion of at least one influenza antigen in the manufacture of a medicament for stimulating an immune response in an elderly human population.~~

~~38~~19. The nucleic acid sequence as set forth in Seq ID 2.

~~39~~20. The nucleic acid sequence as set forth in Seq. ID 4.

~~40~~21. The nucleic acid sequence as set forth in Seq ID 6.

~~41~~22. The polypeptide sequence as set forth in Seq ID 3.

~~42~~23. The polypeptide sequence as set forth in Seq ID 5.

~~43~~24. The polypeptide sequence as set forth in Seq ID 7.

~~44. Use of a composition comprising at least 3 µg of SEQ ID No. 1 in the manufacture of a medicament for stimulating an immune response in an elderly human population, wherein the immune response meets or exceeds one of the following criteria:~~

~~- a seroconversion rate of greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95% or greater than 99%.~~

~~- a seroprotection rate of greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95% or greater than 99%.~~

~~- an average four-fold or greater increase in neutralizing antibody titer at post vaccination.~~

25. The use of claim 1, wherein the dose administered to the human who is at least 65 years old is about a 3 µg to about a 50 µg dose, about a 4 µg to about a 50 µg dose or about a 5 µg to about a 50 µg dose.